GeneDx Holdings Corp. (NASDAQ:WGS) is one of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts. Craig-Hallum Reaffirms Buy on GeneDx (WGS) With $153 Price Target On March 12, 2026, Craig-Hallum reaffirmed its Buy rating on GeneDx Holdings Corp. (NASDAQ:WGS) and maintained a price target of $153 on the company’s stock following data presented at the ACMG Annual Meeting. The data indicated that the company’s whole exome and genome testing notably reduces healthcare resource utilizati ...

Core Insights - The article discusses the 15 most promising stocks under $100 to buy, highlighting their potential for growth and recent developments that may impact investor sentiment. Group 1: GeneDx Holdings Corp. (NASDAQ:WGS) - GeneDx Holdings Corp. has partnered with Zevra Therapeutics to launch a genetic testing program for Niemann-Pick disease type C, aiming to expand access to its ExomeDx test for patients in the US [7][8]. - The program seeks to provide high-quality exome sequencing at no charge to eligible patients, facilitating quicker diagnoses and informed clinical decision-making [7][8]. - De-identified data from the testing will be integrated into GeneDx Infinity, enhancing understanding of disease biology and accelerating the journey from diagnosis to treatment [9]. Group 2: Booz Allen Hamilton Holding Corporation (NYSE:BAH) - Booz Allen Hamilton announced an investment in Hadean, a UK-based tech firm specializing in AI-powered digital wargaming, marking its first international investment [11]. - This collaboration aims to modernize military training and mission rehearsals for the US and its allies through advanced synthetic environments [12]. - The technologies developed are intended to replace legacy systems with scalable and secure capabilities, with applications across defense, civil, intelligence, and national security sectors [13].

Core Viewpoint - Cathie Wood's Ark Invest has been actively purchasing shares of GeneDx Holdings Corp, a small-cap diagnostic testing company, which may indicate potential investment interest as the company has shown strong financial performance and growth prospects [1][2]. Group 1: Ark Invest's Trading Activity - Ark Invest's ETFs have outperformed the S&P 500 in 2025, making their stock picks noteworthy for investors [2]. - Over the last seven trading days, ARKK purchased 79,059 shares and ARKG added 62,328 shares of GeneDx Holdings [3]. - The increased holdings in GeneDx Holdings come after the company reported strong quarterly financial results [3]. Group 2: GeneDx Holdings Financial Performance - GeneDx reported fourth-quarter revenue of $121 million, reflecting a 27% year-over-year increase, and has beaten analyst estimates for earnings per share for 10 consecutive quarters [4]. - For the full fiscal year, GeneDx's revenue reached $427.5 million, up 41% year-over-year, with exome and genome test results volume increasing by 30.5% [5]. - The company projects 2026 revenue between $540 million and $555 million, indicating a positive growth outlook [5]. Group 3: Expansion and Market Position - GeneDx is expanding into new markets, particularly in prenatal diagnostics, which could provide additional growth opportunities [6]. - The company is also seeing increased payer coverage, including Medicaid for exome and genome sequencing in new states, which may enhance its market position [6]. Group 4: Stock Performance - GeneDx stock is currently trading at $81.40, with a 52-week trading range of $55.17 to $170.87, and has experienced a year-to-date decline of 37.8% in 2026 [9].

Core Business Overview - GeneDx has been operating for 25 years, focusing on diagnosing rare diseases, particularly through whole exome and whole genome sequencing technology [1] - The company has recently intensified its commercial efforts since 2021, refining its technology over the past two decades [1] Market Position and Strategy - The core of GeneDx's business involves expert clinical geneticists in the United States, with around 2,000 professionals utilizing exome and genome sequencing as a last-resort diagnostic tool for complex cases [2] - Historically, GeneDx was not widely recognized outside of the expert genetics community, indicating a niche market focus [2]

Core Insights - A landmark study indicates that GeneDx Exome and Genome Testing results in average cost savings of $80,000 per child, alongside overall improved health outcomes [1] Cost Savings - The average cost savings per child from GeneDx testing is reported to be $80,000 [1] Health Outcomes - The study highlights that GeneDx testing leads to overall improved health outcomes for children [1]

Summary of GeneDx Conference Call Company Overview - GeneDx has been operating for 25 years, focusing on diagnosing rare diseases through whole exome and whole genome sequencing technology, which has been refined over two decades [2][4] Core Market Insights - The foundational markets include clinical geneticists and pediatric neurologists, each with approximately 2,000 specialists in the U.S. [5] - 80% of clinical geneticists order exome and genome tests from GeneDx, but they only utilize these tests for about one-third of their patients, indicating significant growth potential [6] - Pediatric neurologists have a lower penetration rate, with only about one-third ordering exome and genome tests, suggesting a long runway for growth [7] NICU Market Potential - GeneDx aims to order over 200,000 tests annually in the Neonatal Intensive Care Unit (NICU), with only 25% of NICUs currently active accounts [9] - Currently, only 5% of NICU patients receive genetic tests, but successful implementations, like Seattle Children's, show that up to 60% could benefit from such tests [9][28] Expansion Markets - GeneDx plans to expand into prenatal testing and general pediatricians, leveraging updated guidelines from the American Academy of Pediatrics [10][44] - The company has launched new products, including GenomeDx Prenatal, to tap into the prenatal market, which has a potential of 150,000 tests annually [48] Sales Strategy and Growth Projections - GeneDx is increasing its sales team from 50 to 75 representatives to enhance market penetration and improve utilization rates among existing accounts [20][22] - The company projects a volume growth of 33%-35%, with 25%-27% expected from foundational markets [24] Challenges and Education Efforts - The slow adoption of exome and genome testing among physicians is attributed to entrenched behaviors and the need for ongoing education about the benefits and advancements in genetic testing [12][14] - GeneDx is focused on dispelling myths about the complexity and cost of genetic tests, aiming to align turnaround times and costs with multi-gene panels [12][18] Customer Experience Enhancements - A new customer experience initiative is being developed to streamline the ordering process for general pediatricians, which is currently in beta testing [45] - The goal is to simplify the diagnostic process and provide tailored reports that are easier for non-expert physicians to understand [45] Conclusion - GeneDx is positioned for significant growth in the genetic testing market, with a focus on expanding its reach into new specialties and improving utilization rates among existing customers. The company is actively addressing challenges related to physician education and market penetration while enhancing customer experience to facilitate adoption.

Core Insights - GeneDx Holdings (WGS) has launched a sponsored genetic testing program in collaboration with Zevra Therapeutics to enhance the diagnosis of Niemann-Pick Disease Type C (NPC), a rare inherited disorder [1][2]. Company Developments - The initiative will provide access to GeneDx's ExomeDx test at no cost for eligible U.S. patients, allowing for quicker and more accurate diagnoses, with results expected in about three weeks [7][10]. - De-identified data from the testing program will be incorporated into GeneDx Infinity, the company's rare disease dataset, to further research and expedite NPC diagnosis [2][3]. - The partnership aims to eliminate barriers to high-quality exome sequencing, thereby improving clinical decision-making for treatable conditions like NPC [3][11]. - GeneDx's market capitalization currently stands at $2.77 billion [6]. Market Context - The genetic testing market is projected to reach a value of $27.32 billion by 2026, with a compound annual growth rate (CAGR) of 11.3% through 2035, driven by factors such as the rising prevalence of chronic and genetic diseases and advancements in technology [12][13]. - The collaboration with Zevra Therapeutics may create opportunities for ongoing partnerships related to the clinical development and commercialization of rare disease therapies [5].

Core Viewpoint - GeneDx Holdings Corp. (WGS) has seen a 4.5% increase in share price over the past four weeks, closing at $88.11, with analysts suggesting a potential upside of 77.8% based on a mean price target of $156.67 [1] Price Targets - The average price target consists of nine estimates ranging from a low of $130.00 to a high of $177.00, with a standard deviation of $16.54, indicating a potential increase of 47.5% to 100.9% from the current price [2] - A low standard deviation suggests a strong agreement among analysts regarding the price targets, which can be a positive indicator for investors [2][9] Analyst Sentiment - There is a growing optimism among analysts regarding WGS's earnings prospects, supported by a trend of upward revisions in earnings estimates, which historically correlates with stock price movements [11] - The Zacks Consensus Estimate for the current year has risen by 29.3% over the past month, with no negative revisions, indicating strong analyst confidence [12] Zacks Rank - WGS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, further supporting the stock's potential upside [13] Conclusion on Price Targets - While the consensus price target may not be a reliable measure of the stock's potential gain, the implied direction of price movement appears to be a useful guide for investors [14]

Core Viewpoint - GeneDx Holdings Corp reported better-than-expected fourth-quarter financial results, with earnings and sales surpassing analyst estimates [1] Financial Performance - Quarterly earnings were 14 cents per share, exceeding the analyst consensus estimate of 11 cents per share [1] - Quarterly sales reached $120.989 million, surpassing the analyst consensus estimate of $120.407 million [1] - The company affirmed its FY2026 sales guidance of $540 million to $555 million [1] Stock Performance - Following the earnings announcement, GeneDx shares fell by 6.1%, trading at $81.82 [1] Analyst Ratings and Price Targets - BTIG analyst Mark Massaro maintained a Buy rating on GeneDx but lowered the price target from $200 to $170 [3] - Piper Sandler analyst David Westenberg maintained an Overweight rating and reduced the price target from $160 to $130 [3]

Core Insights - Polen Capital's fourth-quarter investor letter for the Polen 5Perspectives Small Growth Strategy reported a gross return of -1.3% and a net return of -1.5% for the portfolio, contrasting with a 1.2% return from the Russell 2000 Growth Index [1] - The small-cap asset class is gaining attention due to declining interest rates and improving earnings growth, with a notable focus on biotech stocks [1] - The strategy's name change emphasizes the importance of a multi-perspective approach in investing [1] Company Highlights - GeneDx Holdings Corp. (NASDAQ:WGS) is a genomics company specializing in genetic testing services, which has seen a significant year-over-year increase in testing volumes and improved insurance reimbursement rates [3] - As of February 23, 2026, GeneDx Holdings Corp. had a market capitalization of $2.52 billion, with a one-month return of -16.97% and a 52-week loss of 8.34% [2] - GeneDx is not among the 30 most popular stocks among hedge funds, although its holdings increased from 34 to 39 in the last quarter [4]